Goto Y, et al. Discovery of intratumoral oncolytic bacteria toward targeted anticancer theranostics. Adv Sci (Weinh). 2023;10(20):e2301679.

Article  PubMed  PubMed Central  Google Scholar 

Chen Y, et al. Genetically engineered oncolytic bacteria as drug delivery systems for targeted cancer theranostics. Acta Biomater. 2021;124:72–87.

Article  CAS  PubMed  Google Scholar 

Staedtke V, Sun N, Bai R. Hypoxia-targeting bacteria in cancer therapy. Semin Cancer Biol. 2024;100:39–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khormi MA, et al. Oncolytic bacteria: A revolutionary approach to cancer therapy. Open Life Sci. 2025;20(1):20251076.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsung K, Norton JA. Lessons from coley’s toxin. Surg Oncol. 2006;15(1):25–8.

Article  PubMed  Google Scholar 

Herr HW, Morales A. History of Bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008;179(1):53–6.

Article  PubMed  Google Scholar 

Rius-Rocabert S, et al. Oncolytic bacteria: past, present and future. FEMS Microbiol Lett. 2019. https://doi.org/10.1093/femsle/fnz136.

Article  PubMed  Google Scholar 

Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15(10):615–25.

Article  CAS  PubMed  Google Scholar 

Zhou S, et al. Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma. J Immunother Cancer. 2024. https://doi.org/10.1136/jitc-2023-008238.

Article  PubMed  PubMed Central  Google Scholar 

Sundaresan A, et al. A design of experiments screen reveals that clostridium novyi-NT spore germinant sensing is stereoflexible for valine and its analogs. Commun Biol. 2023;6(1):118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coutermarsh-Ott SL, et al. Effect of Salmonella enterica serovar typhimurium VNP20009 and VNP20009 with restored chemotaxis on 4T1 mouse mammary carcinoma progression. Oncotarget. 2017;8(20):33601–13.

Article  PubMed  PubMed Central  Google Scholar 

Chen W, et al. Bacteria-Driven hypoxia targeting for combined biotherapy and photothermal therapy. ACS Nano. 2018;12(6):5995–6005.

Article  CAS  PubMed  Google Scholar 

Le DT, et al. Results from a phase IIb, Randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study). Clin Cancer Res. 2019;25(18):5493–502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luke JJ, et al. Phase I study of SYNB1891, an engineered E. coli Nissle strain expressing STING Agonist, with and without Atezolizumab in advanced malignancies. Clin Cancer Res. 2023;29(13):2435–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galicia-Carmona T, et al. ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer. Hum Vaccin Immunother. 2021;17(8):2617–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saltzman D, et al. Influence of salmonella-IL2 in combination with FOLFIRINOX on overall and progression-free survival in stage IV metastatic pancreatic cancer. J Clin Oncol. 2025;43(16suppl):2571–2571.

Article  Google Scholar 

Brahmer JR, et al. JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes-Based immunotherapy in patients with NSCLC: results from two phase 1 studies. JTO Clin Res Rep. 2021;2(2):100103.

PubMed  Google Scholar 

Sun J, et al. Efficacy of OK-432 sclerotherapy for different types of lymphangiomas: a review and meta-analysis. Braz J Otorhinolaryngol. 2023;89(4):101270.

Article  PubMed  PubMed Central  Google Scholar 

Stein MN, et al. ADXS31142 Immunotherapy ± Pembrolizumab treatment for metastatic Castration-Resistant prostate cancer: Open-Label phase I/II KEYNOTE-046 study. Oncologist. 2022;27(6):453–61.

Article  PubMed  PubMed Central  Google Scholar 

Dailey KM, et al. The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering. Future Microbiol. 2021;16(5):341–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roe JM, et al. Hacking the immune response to solid tumors: harnessing the anti-cancer capacities of oncolytic bacteria. Pharmaceutics. 2023. https://doi.org/10.3390/pharmaceutics15072004.

Article  PubMed  PubMed Central  Google Scholar 

Arvanitis P, et al. Pathogenesis, diagnosis, and management of cytokine release syndrome in patients with cancer: focus on infectious disease considerations. Curr Oncol. 2025. https://doi.org/10.3390/curroncol32040198.

Article  PubMed  PubMed Central  Google Scholar 

Zhou M, et al. Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies. Front Immunol. 2023;14:1140463.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pierce KM, et al. The evolution and future of targeted cancer therapy: from nanoparticles, oncolytic viruses, and oncolytic bacteria to the treatment of solid tumors. Nanomaterials. 2021. https://doi.org/10.3390/nano11113018.

Article  PubMed  PubMed Central  Google Scholar 

Liu X, et al. Comparison of anticancer activities and biosafety between Salmonella enterica serovar typhimurium ∆ppGpp and VNP20009 in a murine cancer model. Front Microbiol. 2022;13:914575.

Article  PubMed  PubMed Central  Google Scholar 

Yu B, et al. Explicit hypoxia targeting with tumor suppression by creating an obligate anaerobic Salmonella typhimurium strain. Sci Rep. 2012;2:436.

Article  PubMed  PubMed Central  Google Scholar 

Dailey KM, et al. An intravenous pancreatic cancer therapeutic: characterization of CRISPR/Cas9n-modified clostridium novyi-Non toxic. PLoS One. 2023;18(11):e0289183.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He X, et al. Salmonella-based therapeutic strategies: improving tumor microenvironment and bringing new hope for cancer immunotherapy. Med Oncol. 2024;42(1):27.

Article  PubMed  Google Scholar 

Barak Y, et al. Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing. BMC Cancer. 2010;10:146.

Article  PubMed  PubMed Central  Google Scholar 

Niu L, et al. Engineering oncolytic bacteria as precision cancer therapeutics: design principles, therapeutic strategies, and translational perspectives. Protein Cell. 2025.

Mikołajczyk M, Złotkowska D, Mikołajczyk A. Impact on human health of Salmonella spp. and their lipopolysaccharides: possible therapeutic role and asymptomatic presence consequences. Int J Mol Sci. 2024. https://doi.org/10.3390/ijms252211868.

Article  PubMed  PubMed Central  Google Scholar 

Zhou S, et al. Targeted deprivation of methionine with engineered Salmonella leads to Oncolysis and suppression of metastasis in broad types of animal tumor models. Cell Rep Med. 2023;4(6):101070.

Article  CAS